Our peptide drug product platform offers a comprehensive formulation service for oral solid and injectable dosage forms. The formulation team is supported by more than a thousand of scientists and state-of-the-art facilities at our integrated drug product R&D and manufacturing facilities in Wuxi city, Shanghai Waigaoqiao site in China. Both two sites are within 2-hour drive to our peptide API site in Changzhou, providing an integrated peptide API and formulation development and manufacturing solution.
Our oral solid platform provides a variety of dosage forms including tablets, capsules, powder, granules, liquid in bottle, liquid filled hard capsules and softgels with billions of doses annual capacity. In 2021, the team evaluated 2500+ molecules in preformulation studies, delivered 1700+ clinical batches and worked on 20+ late phase and commercial projects
Our injectable platform provide formulation development and manufacturing for solution, emulsion, lyophilized powder and liposome in vial, pre-filled syringe and cartridge. We currently have 1 injectable line (vials, pre-filled syringes and cartridges) in Shanghai Waigaoqiao and plan to add 2 more lines (vials, pre-filled syringes and cartridges) in Wuxi city by the end of 2022.
Do you have peptide drug candidates in development? Attend our webinar co-presented by Yen-Huei Lin, Ph.D. Exec. Director,
Biopharmaceutical Development and Manufacturing at Neuraly and William Fang, Head of Oligo/Peptide Business at WuXi STA about how an integrated CMC partnership was critical in accelerating a novel peptide to phase 1 clinical trial.